(Q40137155)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6311502%20AND%20SRC:MED&resulttype=core&format=json

9 October 2019

review article

1 reference

title

Third-generation and investigational cephalosporins: II. Microbiologic review and clinical summaries (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6311502%20AND%20SRC:MED&resulttype=core&format=json

9 October 2019

Third-Generation and Investigational Cephalosporins: II. Microbiologic Review and Clinical Summaries (English)

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

24 September 2023

author name string

P. Garzone

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6311502

24 September 2023

J. Lyon

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6311502

24 September 2023

V. L. Yu

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6311502

24 September 2023

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=6311502

24 September 2023

publication date

1 September 1983

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6311502%20AND%20SRC:MED&resulttype=core&format=json

full work available at URL

9 October 2019

http://journals.sagepub.com/doi/pdf/10.1177/106002808301700901

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

Drug Intelligence & Clinical Pharmacy

24 September 2023

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6311502%20AND%20SRC:MED&resulttype=core&format=json

9 October 2019

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6311502%20AND%20SRC:MED&resulttype=core&format=json

9 October 2019

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6311502%20AND%20SRC:MED&resulttype=core&format=json

9 October 2019

page(s)

615-622

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6311502%20AND%20SRC:MED&resulttype=core&format=json

Antimicrobial activity of cefmenoxime (SCE-1365).

9 October 2019

cites work

1

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

In vitro evaluation of Ro 13-9904

24 September 2023

2

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

Ceftizoxime (FK 749), a new parenteral cephalosporin: in vitro and in vivo antibacterial activities

24 September 2023

3

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

In vitro evaluation of LY127935 (6059S) compared with cefotaxime, eight other β-lactams and two aminoglycosides

24 September 2023

4

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

Comparative in vitro study in new cephalosporins

24 September 2023

5

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

Comparative Activities of the Oxa-β-Lactam LY127935, Cefotaxime, Cefoperazone, Cefamandole, and Ticarcillin Against Multiply Resistant Gram-Negative Bacilli

24 September 2023

6

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

BL-S786, a new parenteral cephalosporin. I. A collaborative in vitro susceptibility comparison to cephalothin against 5,762 clinical bacterial isolates.

24 September 2023

7

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

Ceftazidime, a pseudomonas-active cephalosporin: in-vitro antimicrobial activity evaluation including recommendations for disc diffusion susceptibility tests

24 September 2023

8

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

In vitro evaluation of cefoperazone

24 September 2023

9

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

In vitro antimicrobial activity of cefotaxime, a new cephalosporin

24 September 2023

10

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

Comparative in vitro activities of SCE-129, sulbenicillin, gentamicin, and dibekacin against Pseudomonas

24 September 2023

11

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

BL-S786, a new parenteral cephalosporin. II. In vitro antimicrobial activity comparison with six related cephalosporins

24 September 2023

12

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

Antibacterial activity of ceftizoxime, a beta-lactamase-stable cephalosporin

24 September 2023

13

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

Comparative in vitro activities of cefotaxime and ceftizoxime (FK749): new cephalosporins with exceptional potency

24 September 2023

14

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

Comparative in vitro studies of Ro 13-9904, a new cephalosporin derivative

24 September 2023

15

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

Antibacterial activity of ceftriaxone (Ro 13-9904), a beta-lactamase-stable cephalosporin

24 September 2023

16

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

Cefoperazone (T-1551), a new semisynthetic cephalosporin: comparison with cephalothin and gentamicin

24 September 2023

17

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

Ro 13-9904, a long-acting broad-spectrum cephalosporin: in vitro and in vivo studies

24 September 2023

18

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

Ro 13-9904: A cephalosporin with a high degree of activity and broad antibacterial activity: an invitro comparative study

24 September 2023

19

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

In vitro activity and beta-lactamase stability of BL-S786 compared with those of other cephalosporins

24 September 2023

20

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

In vitro antimicrobial activity evaluation of cefodizime (HR221), a new semisynthetic cephalosporin

24 September 2023

21

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

Cefuroxime, a new parenteral cephalosporin: collaborative in vitro susceptibility comparison with cephalothin against 5,887 clinical bacterial isolates

24 September 2023

22

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

Comparative in vitro activity of moxalactam, cefotaxime, cefoperazone, piperacillin, and aminoglycosides against gram-negative bacilli

24 September 2023

24

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

In vitro activity of N-formimidoyl thienamycin in comparison with cefotaxime, moxalactam, and ceftazidime

24 September 2023

25

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

Comparison of in vitro activities of eight beta-lactamase-stable cephalosporins against beta-lactamase-producing gram-negative bacilli

24 September 2023

26

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

The in-vitro activity of ceftazidime compared with that of other cephalosporins.

24 September 2023

27

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

Synergy between cefotaxime, cefsulodin, azlocillin, mezlocillin and amino-glycosides against carbenicillin resistant or sensitive Pseudomonas aeruginosa

24 September 2023

28

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

Cefsulodin, a cephalosporin with specific antipseudomonal activity; in vitro studies of the drug alone and in combination

24 September 2023

30

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

In vitro antibacterial activity and susceptibility of cefsulodin, an antipseudomonal cephalosporin, to beta-lactamases

24 September 2023

31

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

Comparative susceptibilities of Pseudomonas aeruginosa to 1-oxacephalosporin (LY 127935) and eight other antipseudomonal antimicrobial agents (old and new).

24 September 2023

32

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

In vitro studies of 1-oxacephalosporin (LY 127935), a new beta-lactam antibiotic

24 September 2023

33

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

Comparison of in vitro activity of GR 20263, a novel cephalosporin derivative, with activities of other beta-lactam compounds

24 September 2023

34

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

24 September 2023

Haemophilus influenzae

36

17

516

Jorgenson J

1980

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

Effect of inoculum size and beta-lactamase production on in vitro activity of new cephalosporins against Haemophilus species

24 September 2023

37

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

A survey of Bacteroides susceptibility in the United States

24 September 2023

38

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

In vitro activity of moxalactam (LY-127935) against anaerobic micro-organisms

24 September 2023

39

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

Differences between Cephalothin and Newer Parenterally Absorbed Cephalosporins in Vitro: A Justification for Separate Disks

24 September 2023

40

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

Comparative in vitro activity of newer cephalosporins against anaerobic bacteria

24 September 2023

41

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

GR 20263, a new broad-spectrum cephalosporin with anti-pseudomonal activity

24 September 2023

42

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

Comparative In Vitro Activity of New Beta-Lactam Antibiotics Against Anaerobic Bacteria

24 September 2023

43

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

Comparative in vitro activity of 1-oxa-beta-lactam (LY127935) and cefoperazone with other beta-lactam antibiotics against anaerobic bacteria

24 September 2023

44

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

Comparison of antibacterial activity of a new cephalosporin, ceftizoxime (FK 749) with other cephalosporin antibiotics

24 September 2023

45

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

24 September 2023

Haemophilus influenzae

46

6

47

Baker C

1980

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

Antibacterial Activity of Cefuroxime, a New Cephalosporin Antibiotic, Compared with That of Cephaloridine, Cephalothin, and Cefamandole

24 September 2023

48

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

Sensitivity testing and synergy

24 September 2023

50

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

Cefmenoxime (SCE-1365), a novel broad-spectrum cephalosporin: in vitro and in vivo antibacterial activities

24 September 2023

51

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

Comparison of in vitro activities of eight beta-lactamase-stable cephalosporins against beta-lactamase-producing gram-negative bacilli

24 September 2023

52

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

Moxalactam therapy for bacterial infections

24 September 2023

53

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

Clinical evaluation of moxalactam

24 September 2023

54

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

In Vitro Antibacterial Activity and β-Lactamase Stability of SCE-129, a New Cephalosporin

24 September 2023

55

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

Hemophilus influenzae type B susceptibility to 17 antibiotics

24 September 2023

56

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

The comparative activity of cefsulodin against anaerobic bacteria of clinical interest: synergy with cefoxitin

24 September 2023

57

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

Ceforanide and cefazolin therapy of pneumonia: comparative clinical trial

24 September 2023

59

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

Evaluation of ceforanide as treatment for staphylococcal and streptococcal endocarditis

24 September 2023

60

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

Cefuroxime compared with penicillin for the treatment of gonorrhea

24 September 2023

61

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

Cefuroxime and ampicillin compared in a double-blind study in the treatment of lower respiratory tract infections

24 September 2023

62

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

Cefotaxime in lower respiratory tract infections compared to cefazolin

24 September 2023

67

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

Treatment of gonorrhea: comparison of cefotaxime and penicillin

24 September 2023

68

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

Cefotaxime and meningitis

24 September 2023

71

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

Clinical and bacteriological results in urinary tract infections with single-dose Ro 13-9904 (Rocephin).

24 September 2023

74

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

Randomized comparative study of moxalactam and cefazolin in the treatment of acute urinary tract infections in adults

24 September 2023

75

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

Moxalactam therapy of infections caused by cephalothin-resistant bacteria: influence of serum inhibitory activity on clinical response and acquisition of antibiotic resistance during therapy

24 September 2023

76

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

Moxalactam Therapy: Its Use in Chronic Suppurative Otitis Media and Malignant External Otitis

24 September 2023

77

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

Enterococcal superinfection and colonization after therapy with moxalactam, a new broad-spectrum antibiotic.

24 September 2023

82

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

American journal of hospital pharmacy

24 September 2023

83

37

858

Foster T

1980

1 reference

https://api.crossref.org/works/10.1177/106002808301700901

24 September 2023

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6311502%20AND%20SRC:MED&resulttype=core&format=json

9 October 2019

1 reference